The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer

Autor: Yael Bar, Kfir Bar, Didi Feldman, Judith Ben- Dror, Meishar Shahoha, Shir Lerner, Shlomit Strulov Shachar, Ahuva Weiss-Meilik, Nachum Dershowitz, Ido Wolf, Amir Sonnenblick
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Breast, Vol 77, Iss , Pp 103777- (2024)
Druh dokumentu: article
ISSN: 1532-3080
DOI: 10.1016/j.breast.2024.103777
Popis: Background: Early invasive ductal carcinoma (IDC) breast cancer often presents with a coexisting ductal carcinoma in situ (DCIS) component, while about 5 % of cases present with an extensive (>25 %) intraductal component (EIC). The impact of EIC on the genomic risk of recurrence is unclear. Methods: Patients with early hormone receptor-positive HER2neu-negative (HR + HER2-) IDC breast cancer and a known OncotypeDX Breast Recurrence Score® (RS) who underwent breast surgery at our institute were included. Using a rule-based text-analysis algorithm, we analyzed pathological reports and categorized patients into three groups: EIC, non-extensive DCIS (DCIS-L), and pure-IDC (NO-DCIS). Genomic risk was determined using OncotypeDX RS. Results: A total of 33 (4.6 %) EIC cases, 377 (57.2 %) DCIS-L cases and 307 (42.8 %) NO-DCIS cases were identified. Patients in the EIC group were younger and had lower tumor grades than other groups. The distribution of genomic risk varied between the groups, with EIC tumors significantly less likely to have a high RS (>25) compared to DCIS-L and No-DCIS tumors (3 % vs 20 % and 20 %, respectively; p = 0.03). When adjusted to age, tumor size, grade and LNs involvement, both DCIS-L and NO-DCIS groups were significantly correlated with a higher probability of high RS compared to the EIC group (OR 12.3 and OR 13.1, respectively; p
Databáze: Directory of Open Access Journals